Agios Pharmaceuticals Inc’s recent filing unveils that its Director FOUSE JACQUALYN A unloaded Company’s shares for reported $0.19 million on Apr 10 ’25. In the deal valued at $25.90 per share,7,497 shares were sold. As a result of this transaction, FOUSE JACQUALYN A now holds 149,220 shares worth roughly $5.15 million.
Then, FOUSE JACQUALYN A bought 7,497 shares, generating $194,172 in total proceeds.
Before that, Burns James William sold 4,005 shares. Agios Pharmaceuticals Inc shares valued at $142,338 were divested by the Chief Legal Officer at a price of $35.54 per share. As a result of the transaction, Burns James William now holds 18,650 shares, worth roughly $0.64 million.
H.C. Wainwright initiated its Agios Pharmaceuticals Inc [AGIO] rating to a Buy in a research note published on February 24, 2025; the price target was $58. A number of analysts have revised their coverage, including Scotiabank’s analysts, who began to cover the stock in mid October with a ‘”a Sector outperform”‘ rating. Leerink Partners revised its rating on September 27, 2024. It rated AGIO as “a Market perform” which previously was an “an Outperform”.
Price Performance Review of AGIO
On Tuesday, Agios Pharmaceuticals Inc [NASDAQ:AGIO] saw its stock jump 2.53% to $34.51. Over the last five days, the stock has gained 3.42%. Agios Pharmaceuticals Inc shares have risen nearly 5.02% since the year began. Nevertheless, the stocks have fallen -27.80% over the past one year.
How much short interest is there in Agios Pharmaceuticals Inc?
A steep rise in short interest was recorded in Agios Pharmaceuticals Inc stocks on 2025-05-15, growing by 0.68 million shares to a total of 4.16 million shares. Yahoo Finance data shows the prior-month short interest on 2025-04-15 was 3.48 million shares. There was a rise of 16.37%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on February 08, 2024 when Cantor Fitzgerald began covering the stock and recommended ‘”an Overweight”‘ rating.
